Chongqing Huabang Shengkai Pharmaceutical Co. LTD

Company Profile:
Chongqing Huabang Shengkai Pharmaceutical Co., LTD., founded in 1994, is a wholly-owned subsidiary of Chongqing Huabang Pharmaceutical under the listed company Huabang Health (Shenzhen Stock Exchange: #002004), engaged in the R&D, production, CDMO, sales and export of API integrated services. The company is located in Chongqing, with 2 production bases and 1 R & D center. The company is committed to becoming the most reliable, characteristic and efficient API supply and service platform. It has been registered and approved and achieved sales in more than 60 countries such as China, the United States, Canada, European Union, Japan, South Korea, Vietnam, Australia, Brazil and so on. It is one of the most reliable suppliers of large pharmaceutical companies at home and abroad.
The company has always adhered to the strategy of technological innovation, relying on excellent chemical research and development and production capacity, to undertake domestic and foreign CDmos, to provide global partners from intermediates to apis, from grams to kilograms to tons, efficient, flexible, high-quality one-stop solutions.
The company's main products are in the fields of anti-tumor, skin medicine, respiratory and anti-infection therapy.

Key Projects/Products:
Bendamustine HCL, Olopatadine HCL, Paricalcitol, Ruxolitinib Phosphate, Bilastine, Levotirizine HCL, Linezolid, Bexarotene, Pyrazinamide, Fluticasone Propionate, Moxifloxacin HCL, Roflumilast, Isoniazid

R&d Pipeline/product line:
Ruxolitinib, Crizotinib, Baricitinib, Upadacitinib, Fulvestrant, Nintedanib esylate, Calcitriol, Carfilzomib, Rupatadine fumarate, Enzalutamide